Xiujuan Jia
Xiujuan Jia has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Jane Wu
Analytical Research Department, Merck Research Laboratories, P.O. Box 2000, RY80L-115, Rahway, NJ 07065-0900, USA
2 shared publications- Tiebang Wang
Merck Research Laboratories, Merck & Co., Inc., P.O. Box 2000, Rahway, NJ 07065, USA
2 shared publications Xiaodong Bu
2 shared publicationsAndreas M. Abend
Analytical Sciences, Analytical Research and Development, MRL, Merck & CO., Inc., Rahway, NJ, USA
1 shared publicationAngela M. Wagner
Sterile and Specialty Products, Pharmaceutical Sciences, MRL, Merck & CO., Inc., Kenilworth, NJ, USA
1 shared publicationChad J. Pickens
Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, 07065, USA
1 shared publication
Latest Publications
- 20 March 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 261, 116826
Characterization of pneumococcal conjugates in vaccine process development by multi-detection hydrodynamic chromatography
- 20 March 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 261, 116826
Characterization of pneumococcal conjugates in vaccine process development by multi-detection hydrodynamic chromatography
- Open Access
- 1 November 2021
- Published by Elsevier in Journal of Chromatography B
- Vol. 1186, 123015
Enabling online determination of the size-dependent RNA content of lipid nanoparticle-based RNA formulations
- 1 November 2021
- Published by Elsevier in Journal of Chromatography B
- Vol. 1186, 123015
Open AccessEnabling online determination of the size-dependent RNA content of lipid nanoparticle-based RNA formulations
- 26 November 2019
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 412 (2) , 377-388
Ultrahigh performance liquid chromatography methods facilitate the development of glucose-responsive insulin therapeutics
Insulin oligosaccharide conjugates hold promise as potential glucose-responsive insulins (GRIs), which can improve the therapeutic index of insulins and mitigate the risk of hypoglycemia. A key challenge for the analytical development of such molecules is finding an efficient method to characterize the purity and impurities of conjugated insulins. Using the S-Matrix Fusion QbD-ultrahigh performance liquid chromatography (UHPLC) integrated system, we were able to quickly screen and develop two short UHPLC methods. These methods were used to support process development, clinical batch drug substance (DS) release, and stability studies of MK-2640, an insulin oligosaccharide conjugate. Both methods used a Waters CSH C18 column, with a shallow gradient of acetonitrile to aqueous mobile phase containing 25 mM sodium perchlorate and 0.05% perchloric acid. The 10-min run time method was well suited for process development and monitoring as it was able to separate the main product, MK-2640, six oligosaccharide-substituted recombinant human insulin (RHI) impurities, A21 deamidated MK-2640, and the starting material RHI. The 13-min run time method provided improved separation of the major impurities and demonstrated good chromatographic reproducibility on different instruments or using columns from different lots of stationary phase, which made it ideal for the final DS release. Validation of the 13-min method demonstrated great linearity for both the MK-2640 main peak and its related impurities, low limit of detection (0.02%), and limit of quantitation (0.05%). The high specificity of the method allowed the separation of the degradation products from main peak, thus makes it suitable for stability monitoring. The major impurities in the DS were characterized by two-dimensional liquid chromatography-mass spectrometry (2D-LC-MS).
- 26 November 2019
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 412 (2) , 377-388
Ultrahigh performance liquid chromatography methods facilitate the development of glucose-responsive insulin therapeutics
Insulin oligosaccharide conjugates hold promise as potential glucose-responsive insulins (GRIs), which can improve the therapeutic index of insulins and mitigate the risk of hypoglycemia. A key challenge for the analytical development of such molecules is finding an efficient method to characterize the purity and impurities of conjugated insulins. Using the S-Matrix Fusion QbD-ultrahigh performance liquid chromatography (UHPLC) integrated system, we were able to quickly screen and develop two short UHPLC methods. These methods were used to support process development, clinical batch drug substance (DS) release, and stability studies of MK-2640, an insulin oligosaccharide conjugate. Both methods used a Waters CSH C18 column, with a shallow gradient of acetonitrile to aqueous mobile phase containing 25 mM sodium perchlorate and 0.05% perchloric acid. The 10-min run time method was well suited for process development and monitoring as it was able to separate the main product, MK-2640, six oligosaccharide-substituted recombinant human insulin (RHI) impurities, A21 deamidated MK-2640, and the starting material RHI. The 13-min run time method provided improved separation of the major impurities and demonstrated good chromatographic reproducibility on different instruments or using columns from different lots of stationary phase, which made it ideal for the final DS release. Validation of the 13-min method demonstrated great linearity for both the MK-2640 main peak and its related impurities, low limit of detection (0.02%), and limit of quantitation (0.05%). The high specificity of the method allowed the separation of the degradation products from main peak, thus makes it suitable for stability monitoring. The major impurities in the DS were characterized by two-dimensional liquid chromatography-mass spectrometry (2D-LC-MS).
- 1 April 2006
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 41 (1) , 43-47
Determination of ruthenium in pharmaceutical compounds by graphite furnace atomic absorption spectroscopy
- 1 April 2006
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 41 (1) , 43-47
Determination of ruthenium in pharmaceutical compounds by graphite furnace atomic absorption spectroscopy
- 1 September 2003
- Published by Elsevier in Microchemical Journal
- Vol. 75 (2) , 103-107
Isolation and analysis of trace level of silicone oil in pharmaceutical bulk drug substance by ICP-AES
- 1 September 2003
- Published by Elsevier in Microchemical Journal
- Vol. 75 (2) , 103-107
Isolation and analysis of trace level of silicone oil in pharmaceutical bulk drug substance by ICP-AES